secwatch.observer — SEC 8-K summary
======================================

Issuer:     NutriBand Inc. (NTRB)
CIK:        0001676047
Form:       8-K
Filed at:   2023-03-29T23:59:59+00:00
Accession:  0001213900-23-023937
Event type: debt
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nutriband secures $2M credit line for AVERSA Fentanyl commercialization
-----------------------------------------------------------------------

- Three-year $2,000,000 credit line at 7% interest, non-convertible to common stock.
- Proceeds to fund FDA approval process and commercial manufacturing of AVERSA Fentanyl.
- AVERSA Fentanyl is an abuse-deterrent fentanyl transdermal system using proprietary technology.
- Potential peak annual US sales estimated at $80M-$200M per 2022 market analysis.
- Financing is non-dilutive, supporting growth strategy without equity dilution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676047/000121390023023937/0001213900-23-023937-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676047/000121390023023937/ea175942-8k_nutriband.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-023937

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer